Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
700 participants
OBSERVATIONAL
2024-04-15
2024-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Determining How the Nervous System Processes Pain in Adults With Fibromyalgia
NCT00496886
Functional Assessment of the Patient With Fibromyalgia and Its Relation to Health: Fibromyalgia and Sarcopenia
NCT06253273
Assessment of the Functional Capacity of Patients with Fibromyalgia: Clinical Validity
NCT06819930
Functional Capacity Determinants in Fibromyalgia
NCT07318441
Analysis of Facial Expressions for Pain Recognition in Fibromyalgia: Using Artificial Intelligence and Biomarkers
NCT06813352
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study will be conducted among people suffering from fibromyalgia and associated with the National Association of Fibromyalgia Patients FIBRO-MY. The study will be conducted using an online survey created in a "Google form". The survey will include such research tools as: WHODAS 2.0 disability assessment questionnaire, Fibromyalgia Impact Questionnaire FIQ, Beck Depression Inventory BDI. The study will be conducted based on the International Classification of Functioning Disability and Health. Appropriate statistical models will be selected to analyze the data and the results will be presented in a descriptive form.
Description of research tools:
1. The WHO Disability Assessment Schedule (WHODAS 2.0) 36-item is used to measure general disability and disability in six domains: Do1 Cognition (6 items), Do2 Mobility (5 items), Do3 Self-care (4 items), Do4 Getting along (5 items), Do5 Life activities (8 items), and Do6 Participation (8 items). During the interview, the response refers to the last 30 days. Answers to the questions are rated on a 5-point scale identifying the level of di culty or problem (1 = none; 2 = mild; 3 = moderate; 4 = severe; 5 = extreme or cannot to do). The obtained results are converted according to the instructions on the scale from 0 to 100. When assessing the level of disability with the WHODAS 2.0, the following scale (consistent with the ICF) was used: no disability or an insufficient problem (0-4%), mild disability or a small problem (5-24%), moderate disability or a significant problem (25-49%), severe disability or a big problem (50-95%), and extreme disability or a total problem (96-100%).
2. The Fibromyalgia Impact Questionnaire (FIQ) The FIQ questionnaire allows us to assess the impact of fibromyalgia on the quality of life of patients. The reminder period for FIQ is 1 week. FIQ consists of 20 items examining 10 subscales (scoring dimensions): Physical functioning, Well-being, Work related, Do work, Pain, Fatigue, Rested, Stiffness, Anxiety, Depression. Individual domains are scored according to the conversion key. Once the initial scoring is complete, the scores obtained are converted to normalized scores from 0 to 10, with 0 meaning no impairment and 10 meaning maximum impairment. The total score is expressed on a scale of 0-100. Higher scores mean a greater (negative) impact of the disease on the patient's quality of life.
3. The Beck's Depression Inventory (BDI) The BDI contains 21 items on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms). The reminder period for BDI is 2 weeks. Anxiety symptoms are not assessed, but affective, cognitive, somatic, and vegetative symptoms are considered, reflecting the Diagnostic and Statistical Manual (DSM-IV) criteria for major depression. The minimum score is 0 and the maximum score is 63. Higher scores indicate greater severity of symptoms. In non-clinical populations, scores above 20 indicate depression. In people diagnosed with depression, scores of 0-13 indicate minimal depression, 14-19 (mild depression), 20-28 (moderate depression) and 29-63 (severe depression).
At least 700 people are planned to be included in the study. The study will cover people belonging to the National Association of Fibromyalgia Patients FIBRO-MY. These will be adults diagnosed with fibromyalgia who give informed consent to participate in the study and decide to complete the electronic survey. Since the study will be conducted based on an anonymous online survey, at the beginning of the study there will be information about expressing informed consent to participate in the study and a note that completing the survey is a confirmation of consent.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CROSSOVER
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
people with fibromyalgia
People with fibromyalgia in Poland. The study does not include any intervention. The collected data, in a cross-sectional study, are intended to assess the functioning and disability of people with fibromyalgia using standardized questionnaires such as: WHODAS 2.0, FIQ, BDI.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* People suffering from fibromyalgia
* People who give informed consent to participate in the study
Exclusion Criteria
* Underage persons
* People without fibromyalgia
* People who do not give informed consent to participate in the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Rzeszow
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Agnieszka Sozanska
dr hab. n. o zdr., prof. UR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Agnieszka Sozańska
Role: PRINCIPAL_INVESTIGATOR
University of Rzeszow
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Rzeszow
Rzeszów, Podkarpackie Voivodeship, Poland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
disability fibromyalgia
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.